text: Enzalutamide, a second-gen AR blocker,
  Approved for patients whose treatment's a shocker,
  Castration-resistant prostate cancer it combats,
  When androgen deprivation therapy falls flat.
  
  Over 80% of patients, bone metastases they face,
  Enzalutamide steps in to slow down the chase,
  Binding to the AR, no nuclear translocation,
  Androgen signaling's shut down, no activation.
  
  But prostate cancer cells, they don't back down,
  Develop resistance, find a way around,
  In patients and labs, studies have shown,
  Enzalutamide resistance, a challenge to own.
  
  Genetic mutations and splice variants of the AR,
  Mechanisms of resistance, they've come so far,
  Signaling pathways, they find a bypass,
  Androgen signaling, they cleverly surpass.
  
  Intratumoral androgen biosynthesis in play,
  Prostate tumor cells, their own androgens they sway,
  Lineage plasticity, a factor to consider,
  Tumor microenvironment, it couldn't be bigger.
  
  To overcome these hurdles, strategies they devise,
  Enzalutamide resistance, they aim to neutralize,
  But problems arise, solutions are sought,
  A battle against resistance, fiercely fought.
  
  Emerging questions, concerns on the rise,
  Opportunities to study, where knowledge lies,
  Enzalutamide resistance, a puzzle to solve,
  In the quest for a cure, they'll continue to evolve.